(Q38219225)

31 August 2017

title

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy (English)

1 reference

Adaptive radiation therapy

31 August 2017

main subject

0 references

author

Katarina Sjögreen Gleisner

Katarina Sjögreen Gleisner

6

0 references

Carlo Chiesa

Carlo Chiesa

3

0 references

Glenn D Flux

Glenn Flux

8

0 references

Lidia Strigari

Lidia Strigari

1

0 references

Manuel Bardies

Manuel Bardies

4

0 references

Michael Lassmann

Michael Lassmann

7

0 references

author name string

Mark Konijnenberg

2

1 reference

31 August 2017

Yong Du

5

1 reference

31 August 2017

publication date

11 June 2014

1 reference

31 August 2017

number of pages

13

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

31 August 2017

volume

41

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

1976-1988

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-014-2824-5

31 August 2017

exact match

0 references

cites work

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Calculation of integrated biological response in brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of prec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Treatment of Graves' Hyperthyroidism with Radioiodine: Results of a Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Liver disease induced by radioembolization of liver tumors: description and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

EANM procedure guidelines for therapy of benign thyroid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy

21 January 2018

1 reference

12 December 2020

Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer

1 reference

12 December 2020

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail

1 reference

12 December 2020

Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres

1 reference

12 December 2020

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method

1 reference

12 December 2020

Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.

1 reference

12 December 2020

Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.

1 reference

12 December 2020

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants

1 reference

12 December 2020

Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer

1 reference

12 December 2020

Dosimetry in nuclear medicine therapy: radiobiology application and results

1 reference

12 December 2020

Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.

1 reference

12 December 2020

Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan

1 reference

12 December 2020

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

1 reference

12 December 2020

Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass

1 reference

12 December 2020

The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma

1 reference

12 December 2020

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"

1 reference

12 December 2020

The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer

1 reference

12 December 2020

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

12 December 2020

Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy

1 reference

12 December 2020

Biological optimization of heterogeneous dose distributions in systemic radiotherapy

1 reference

12 December 2020

Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation

1 reference

12 December 2020

Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma

1 reference

12 December 2020

Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

1 reference

12 December 2020

A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism

1 reference

12 December 2020

A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease

1 reference

12 December 2020

Individualized dosimetry in the management of metastatic differentiated thyroid cancer

1 reference

12 December 2020

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

1 reference

12 December 2020

10.1007/S00259-014-2824-5

Identifiers

DOI

1 reference

31 August 2017

1 reference